Haloperidol Kinetics in Senile Dementia
The number of patients with dementie disease has increased and psychotic symptoms and behavioral disturbances with dementia are also observed.1 In these cases, antipsychotic drugs such as haloperidol has been widely used, the dosage generally based on a doctor’s clinical experience. Particularly in aged patients, individual deviation in pharmacokinetics becomes large and therapeutic dosage may often induce side effects such as the extrapyramidal syndrome. Thus, in the aged, it is especially important to establish an administration scheme on the basis of pharmacokinetic findings. Haloperidol is the most commonly prescribed antipsychotic drugs. Plasma concentration has been examined for all of the antipsychotic drugs, but haloperidol is considered the ideal agent for such studies because of the drug’s relatively simple metabolic pathway.2 Although, there have been many reports on the plasma concentration and clinical effects of haloperidol, those on effective plasma levels in aged patients are few. In the present study, we compared the plasma levels of haloperidol in the démentie patients above the age of 65 years who were given haloperidol due to psychotic symptoms such as delirium, hallucination, delusion and behavioral disturbances with those in schizophrenic patients under the age of 65.
KeywordsAntipsychotic Drug Psychotic Symptom Behavioral Symptom Behavioral Disturbance Senile Dementia
Unable to display preview. Download preview PDF.
- Forsman A, Folsch G, Larsson M, Ohman R (1977) On the metabolism of haloperidol in man. Curr. Then Res. 21: 606–617Google Scholar
- American Psychiatric Association. DSM-III: Diagnostic and Stastical Manual of Mental Disorders. 3rd. Washington, DC: APA, 1980Google Scholar
- Cahn LA, Diesfeldt HFA (1973) The use of neuroleptics in the treatment of dementia in old age. Psych Neurol Neurochir 76: 411–420Google Scholar
- Reifler BV, Larson E, Cox G (1982) Treatment results at a multispecialty clinic for the impaired elderly and their families. J Am Geriatr Soc 29: 579–582Google Scholar
- Aoba A, Yamaguchi N, Shido M (1986) Difference in the age effect on plasma neuroleptic levels between haloperidol and chlorpromazine in psychiatric patients. In: Clinical and Pharmacological Studies in Psychiatric Disorders. John Libbey and Company Ltd., London: 222–229Google Scholar